Recce targets A$15.8M to advance anti-infectives into confirmatory trials

Sydney-based Recce Pharmaceuticals has secured A$5.0 million via private placement and launched a A$10.8 million entitlement offer to support Phase 3 trials of its synthetic anti-infectives for diabetic foot infections (DFI) and acute bacterial skin and skin structure infections (ABSSSI).

In an April 10 announcement, the company said the combined A$15.8 million raise (before costs) will primarily fund a registrational Phase 3 trial for its topical DFI treatment in Indonesia, expected to drive potential revenue in 2026. Additional funds will initiate a Phase 3 ABSSSI trial in Australia, following a successful Phase 2 study, and support other clinical activities, an IND filing with the FDA, and general working capital.

“We are delighted to receive further support from an existing Australian-based shareholder and are pleased to launch an entitlement offer to all shareholders to acquire new shares at the same price as the placement,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “Proceeds from the capital raising will be used to support a Registrational Phase III clinical trial for diabetic foot infections in Indonesia and a Registrational Phase 3 for ABSSSI across Australia, following a recently announced Phase 2 ABSSSI clinical study achieving all endpoints.”

In a company press release, Recce CEO James Graham said the firm was “delighted to receive further support from an existing Australian-based shareholder” and had launched an entitlement offer allowing all shareholders to acquire new shares at the same price as the placement.

According to The Australian’s Stockhead column, Recce views the funding as a key inflection point for the company. He cites strong support from an existing investor and board-level participation in the entitlement offer. The publication noted Recce’s platform is aimed at conditions vulnerable to antibiotic resistance. The company positions its synthetic anti-infective pipeline as a potential “new standard of care” for serious bacterial infections.

As of April 9, 2025, Recce Pharmaceuticals Ltd (ASX: RCE) experienced a dip in its stock price, closing at A$0.30, down 7.69% from the previous close of A$0.325.